U.S. Market Community

Nu Holdings takes a hit as Brazil’s economy weakens and loan losses rise, but the core idea stays the same: a branch-free bank that keeps gaining customers and selling them more services. The next chapters—getting bigger in Mexico, testing new AI-driven advice, and a possible move into the U.S.—could change how investors see the business, but there are real risks tied to Brazil and credit quality.Read more

This company brings in money from old debts it expects to collect, but recent accounting write-downs and tired messaging have shaken confidence. If it starts showing real progress on data and automation—or gets bought by a more ambitious owner—the story could change fast.Read more

Spectral AI is building a tool that helps doctors spot which wounds are likely to heal and which ones need faster, more serious care, including burns that can be hard to judge by eye. The big question is whether regulators sign off and whether hospitals and emergency rooms turn early interest into real orders before cash runs tight.Read more

Horizon Aircraft is building a small plane that can take off like a helicopter but fly most of the trip like a normal airplane, aiming to avoid many of the headaches tied to charging-only designs. The story hinges on whether its patents, early customer interest, and a clearer certification path can turn into real deliveries before delays and funding needs get in the way.Read more

Intel’s chip business looks like it has stopped getting worse, but the real question is whether its manufacturing arm can turn from a cash drain into a real profit engine. New leadership and growing outside interest hint at a path forward, while the story also explains what has to go right for that turnaround to actually matter.Read more

Moody’s sits at the center of the global bond market, getting paid whenever governments and companies raise money, while also building a steadier subscription-style data and software business. The main question is whether new tools like AI weaken its role or end up strengthening it as debt markets and regulation keep growing.Read more

BrightSpring’s growth story may look like home health at first glance, but the real engine is its specialty and long-term care pharmacy business, where patients rarely switch providers once treatment starts. As the company finishes cleanup work from past restructuring, improving efficiency and lower debt could change how the market views the business.Read more

Lightwave Logic aims to shift from years of lab work into real sales, with its first meaningful production and licensing income expected later this decade. The big question is whether major chip and networking partners and top-tier customers adopt its polymer-based optical technology in time—and whether the company can scale manufacturing without running out of money.Read more

Arcturus Therapeutics’ biggest vaccine partner has soured on their relationship, and that fallout could unexpectedly free the company to team up with new pharma giants. The story digs into why this breakup matters, what new partners like Sanofi or BioNTech might want from Arcturus’ RNA platform, and what could still derail the upside.Read more